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University of Nebraska Medical Center, Omaha, NE, United States, 4 Division of Gastroenterology and Hepatology,
Department of Biochemistry and Molecular Biology, Center for Basic Research in Digestive Diseases, Mayo Clinic,
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This review describes the influence of ethanol consumption on hepatic lipophagy,
a selective form of autophagy during which fat-storing organelles known as lipid
droplets (LDs) are degraded in lysosomes. During classical autophagy, also known
as macroautophagy, all forms of macromolecules and organelles are sequestered in
autophagosomes, which, with their cargo, fuse with lysosomes, forming autolysosomes
in which the cargo is degraded. It is well established that excessive drinking accelerates
intrahepatic lipid biosynthesis, enhances uptake of fatty acids by the liver from the
plasma and impairs hepatic secretion of lipoproteins. All the latter contribute to alcohol-
induced fatty liver (steatosis). Here, our principal focus is on lipid catabolism, specifically
the impact of excessive ethanol consumption on lipophagy, which significantly influences
the pathogenesis alcohol-induced steatosis. We review findings, which demonstrate
that chronic ethanol consumption retards lipophagy, thereby exacerbating steatosis.
This is important for two reasons: (1) Unlike adipose tissue, the liver is considered
a fat-burning, not a fat-storing organ. Thus, under normal conditions, lipophagy in
hepatocytes actively prevents lipid droplet accumulation, thereby maintaining lipostasis;
(2) Chronic alcohol consumption subverts this fat-burning function by slowing lipophagy
while accelerating lipogenesis, both contributing to fatty liver. Steatosis was formerly
regarded as a benign consequence of heavy drinking. It is now recognized as the
“first hit” in the spectrum of alcohol-induced pathologies that, with continued drinking,
progresses to more advanced liver disease, liver failure, and/or liver cancer. Complete
lipid droplet breakdown requires that LDs be digested to release their high-energy cargo,
consisting principally of cholesteryl esters and triacylglycerols (triglycerides). These
subsequently undergo lipolysis, yielding free fatty acids that are oxidized in mitochondria
to generate energy. Our review will describe recent findings on the role of lipophagy in
LD catabolism, how continuous heavy alcohol consumption affects this process, and
the putative mechanism(s) by which this occurs.
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ALCOHOL ABUSE CAUSES LIVER
INJURY
Heavy drinking is a major cause of liver disease worldwide
(O’Shea et al., 2010). Current trends indicate that, in the
United States, between 2007 and 2014, alcohol-induced liver
disease (AILD) became the second most frequent cause of
cirrhosis and hepatocellular carcinoma (HCC)-related mortality
after non-alcoholic fatty liver disease (NAFLD) (Kim et al.,
2019). Fatty liver (steatosis) is the earliest response to excessive
drinking in 90% or more of alcohol abusers (O’Shea et al., 2010;
You and Arteel, 2019). Steatosis is characterized by excessive
deposition of fat, seen microscopically as intracellular lipid
droplets (LDs). These are hydrophobic islands of stored fat,
each surrounded by a phospholipid monolayer, which, itself,
harbors specific proteins that maintain LD integrity. Under
the microscope, LDs can be seen suspended alone in the
soluble cytoplasm (cytosol) or in physical contact with other
membranous organelles, including the endoplasmic reticulum
(ER), from which LDs are believed to originate (Ploegh, 2007;
Fei et al., 2009; Choudhary et al., 2015). LDs also interact
with mitochondria, lysosomes, peroxisomes, and membranes
of the Golgi apparatus (Barbosa et al., 2015). Each of the
latter organelles has a functional interaction with LDs, the
extent of which appears to depend on the cell’s lipid content
(Krahmer et al., 2018).
In this review, the terms “autophagy” and “lipophagy” will,
be used interchangeably or together. The two are closely-
linked, as LDs are taken up and degraded with other cellular
constituents, by “bulk autophagy.” During “true lipophagy,” LDs
are selectively taken up and degraded. In addition, the classical
autophagy/lipophagy pathway, mentioned in the Abstract has
some non-canonical variations to be described herein.
AILD IS LINKED TO ETHANOL
OXIDATION
The liver sustains the greatest injury after excessive drinking
because it is the principal site of ethanol oxidation (metabolism)
(Lieber and DeCarli, 1991; Osna et al., 2017), as depicted in
Figure 1. The bulk of hepatic ethanol oxidation is catalyzed
by alcohol dehydrogenase (ADH) and cytochrome P450
2E1(CYP2E1). Catalase, an enzyme, which inhabits peroxisomes
and is abundant in liver, has an accessory function in hepatic
ethanol oxidation, but a more prominent role in brain ethanol
metabolism (Zimatkin et al., 2006). ADH, the primary oxidative
enzyme, is located in the liver cytosol (soluble cytoplasm).
ADH has a high catalytic efficiency (Kcat) and a high affinity
(Km ethanol = 1–2 mM) for ethanol as a substrate. CYP2E1 is
predominantly associated with the membranes of the smooth
ER. It has a lower affinity for ethanol (Km ethanol = 10–20 mM)
and a lower Kcat than ADH. All three enzymes oxidize ethanol
to generate acetaldehyde, which is toxic because it is highly
reactive and covalently binds to proteins, lipids and nucleic
acids (Kenney, 1982; Donohue et al., 1983; Brooks and Zakhari,
2014). In hepatocytes, acetaldehyde’s toxicity is minimized
because it is rapidly oxidized to acetate by the mitochondrial
aldehyde dehydrogenase2 (ALDH2). Both ADH-catalyzed
ethanol oxidation to acetaldehyde and ALDH2-catalyzed
acetaldehyde oxidation to acetate utilize nicotinamide adenine
dinucleotide (NAD+) as a hydrogen and electron acceptor.
Together, both reactions generate excess quantities of NADH,
which lowers the intracellular NAD+/NADH ratio, also known
as the cellular redox potential. The latter change in redox
initiates significant metabolic shifts toward reductive synthesis
by accelerating the synthesis and slowing the oxidation of
fatty acids, thereby exacerbating steatosis. In addition, ethanol
oxidation stimulates fatty acid biosynthesis by enhancing de
novo synthesis of lipogenic enzymes, the syntheses of which
are governed by activation of three transcription factors: the
sterol regulatory element binding protein-1c (SREBP-1c), the
carbohydrate response element binding protein (ChREBP)
and early growth response-1 (Egr-1). We and others have
described the induction and regulatory features of these factors
in other articles and reviews (You et al., 2002; Liangpunsakul
et al., 2013; Thomes et al., 2013b; Thomes and Donohue, 2017;
You and Arteel, 2019).
CYP2E1, the other major ethanol metabolizing enzyme is
unique in two ways: (1) The enzyme is induced by ethanol,
which elevates CYP2E1’s intracellular content (Lieber, 1970,
2004; Roberts et al., 1995), thereby accelerating the overall
rate of ethanol oxidation; (2) CYP2E1 possesses a unique
catalytic cycle, coupled with a broad substrate specificity. The
latter properties allow the enzyme to produce, not only higher
levels of acetaldehyde but also greater quantities of other
reactive oxygen species (ROS), including hydroxyethyl radicals
(•CH3CH2OH), hydroxyl radicals (•OH), and superoxide anions
(O−2 ). Superoxide can undergo secondary reactions with nitric
oxide to form peroxynitrite (OONO−), which can covalently
bind to tyrosine residues on proteins (Osna et al., 2004). All the
aforementioned reactive species are unstable, but they heighten
oxidant stress in the hepatocyte to enhance hepatocellular
damage (Wu et al., 2012; Yang et al., 2012) (also see Takahashi).
It is now clear that development of alcohol-induced fatty
liver is the “first hit” that propagates injury, as described
in the next section.
METABOLIC SOURCES OF
ALCOHOL-INDUCED HEPATIC LIPIDS
AND THEIR HEPATOTOXICITY
Alcohol-induced fatty liver was reported in humans (Buck,
1948) decades before the metabolic pathways affected by heavy
drinking were revealed and well before it was discovered that
certain fatty acids are hepatotoxic (Savary et al., 2012). Hepatic
fatty acid (and lipid droplet) accumulation after alcohol abuse
arises from: (1) accelerated hepatic lipogenesis (You et al.,
2002; You and Crabb, 2004); (2) enhanced fatty acid import
into the liver from the plasma (Wei et al., 2013); (3) defective
secretion of lipoproteins (e.g., very low density lipoproteins
VLDLs) from the liver into the plasma, resulting in their
hepatic retention (Kharbanda et al., 2009); (4) reduced fatty
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FIGURE 1 | Ethanol metabolism and hepatic oxidant stress. Ethanol is oxidized principally in liver hepatocytes by ADH, CYP2E1, and catalase to acetaldehyde
(Ach). Ach is a highly reactive intermediate that, itself, covalently binds to protein or can undergo secondary reactions to form MAA (see text). CYP2E1 is induced by
ethanol and produces radicals, including superoxide and hydroxyl radicals, which by themselves are reactive and can undergo secondary reactions with PUFA,
producing ROS and RNS as defined in this figure and in the text. The latter reactive molecules can also form adducts with proteins.
acid oxidation (FAO) by mitochondria (Fischer et al., 2003);
and now, (5) decelerated lipophagy (Rasineni et al., 2017;
Schulze et al., 2017a).
Steatosis from heavy drinking elevates intrahepatic levels of
saturated and polyunsaturated fatty acids (PUFA). The latter
are particularly reactive, because their double bonds, allow
them to combine with hydroxyl radicals (•OH) derived from
ethanol oxidation and/or mitochondrial respiration, to form lipid
peroxides. These undergo subsequent modifications, including
the iron-driven Fenton reaction and peroxide fragmentation
to produce highly reactive lipid aldehydes, including 4-
hyroxynonenal (4-HNE) and malondialdehyde (MDA), each
of which covalently binds to proteins (Houglum et al., 1990).
Acetaldehyde, generated from ethanol oxidation can also
react with MDA to form a larger, highly reactive hybrid
molecule, malodialdehyde-acetaldehyde (MAA) that binds to
proteins, forming MAA adducts (Tuma et al., 1996, 2001;
Figure 1) Proteins that bear such adducts exhibit altered
biological function as well as proinflammatory and profibrogenic
properties that can exacerbate liver injury beyond simple
steatosis (Kharbanda et al., 2001, 2002; Tuma, 2002). It is
also noteworthy that earlier in vitro studies revealed that
substoichiometric concentrations of acetaldehyde (Ach) alone
can form adducts with a specific lysine residue on the alpha
subunit of tubulin to disrupt its polymerization into functional
microtubules (Smith et al., 1989) These findings suggest that
metabolically-derived Ach has similar properties in vivo, which
may explain how chronic ethanol consumption disrupts vesicle
trafficking in hepatocytes during autophagy. Figure 2 depicts
such a scenario.
LD CATABOLISM
Until 2009, it was held that LDs are degraded by lipases in
the cytosol and by the lysosomal acid lipase (LAL), but do
not undergo macroautophagy. That concept was discarded
after Singh et al. (2009) demonstrated the macroautophagic
degradation of LDs. These investigators also added the term,
“lipophagy” to the list of autophagic organelle degradation
pathways. That list includes mitophagy (mitochondria)
(Lemasters, 2005), pexophagy (peroxisomes) (Katarzyna
and Suresh, 2016), ERphagy or reticulophagy (endoplasmic
reticulum), (Schuck et al., 2014) ribophagy (ribosomes) (An
and Harper, 2018) nucleophagy (nuclei) (Mochida et al.,
2015), lysophagy (lysosomes) (Hung et al., 2013), and in
photosynthetic cells, chlorophagy (chloroplasts) (Ishida et al.,
2008; Wada et al., 2009).
Schulze et al. (2017b) reviewed the multiple pathways by
which LDs are degraded in liver cells. These are depicted
in Figure 3. Macrolipophagy is the canonical vesicular
pathway during which LDs (or portions thereof) are selectively
sequestered in autophagosomes, which are then trafficked by
microtubules to fuse with lysosomes, forming autolysosomes
in which the LDs_is/are degraded. During microlipophagy,
LDs directly interact with (or are engulfed by) lysosomes in an
endocytosis-like manner, for direct lipolysis of the LD contents.
Chaperone-mediated autophagy (CMA), carries out the selective
lysosomal degradation of specific proteins that reside on the
LD membrane. Two such proteins are the perilipins 2 and 3
(PLIN2 and PLIN3) (Kaushik and Cuervo, 2016) These proteins
are targeted by CMA to the lysosome because each carries,
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FIGURE 2 | Postulated mechanism by which acetaldehyde impairs microtubule function. Acetaldehyde (Ach) is generated from ethanol oxidation. Due to its high
reactivity, it can, form adducts with the α-subunit of tubulin, to inhibit microtubule (MT) polymerization. Such inhibition impairs MT-dependent processes, including the
movement of LD-bearing autophagosomes to lysosomes for degradation of LDs.
in its primary sequence, a specific pentapeptide (lys-phe-glu-
arg-gln or KFERQ), which is recognized by and binds to the
cytosolic form of the 70 kDa heat shock constitutive protein,
(Hsc70) a chaperone, that directs each PLIN to the lysosomal
membrane. There, the lysosome-associated membrane protein
2A (LAMP2A) facilitates each protein’s internalization and
degradation. The removal and degradation by CMA of PLINS
from the LD membrane enhances recruitment of cytosolic
lipases, including the cytoplasmic adipose triglyceride lipase
(ATGL) to initiate lipolysis of the LD contents (Kory et al.,
2015). In the context of this review, it is noteworthy that,
prior to its degradation by CMA, PLIN 2 is phosphorylated
by the energy-sensing adenosine monophosphate-activated
kinase (AMPK) (Kaushik and Cuervo, 2016). The kinase is
activated by nutrient deficit but inactivated by chronic alcohol
consumption (You and Crabb, 2004; You et al., 2004). The
reader should note that Figure 3 identifies this and other specific
steps in the lipophagic pathways illustrated, that are impaired
by alcohol abuse.
PLIN2 is also ubiquitylated and degraded by the ubiquitin-
proteasome system (UPS) (Xu et al., 2005). Ubiquitylation is
a post-translational modification, during which polymers of
ubiquitin, an 8.5 kDa polypeptide, are covalently attached to
protein substrates at their free NH2-termini or at the epsilon-
amino groups of their internal lysine residues. The polyubiquitin
chain is a signal for degradation of the protein substrate by
the 26S proteasome (Ciechanover et al., 1980; Ciechanover,
1994; Bercovich et al., 1997; Ciechanover and Schwartz, 2004).
Evidence indicates that the UPS regulates the content of PLIN2 in
the cytosol by degrading its cytosolic form, but after it is localized
in the LD membrane, PLIN2 evades UPS-catalyzed proteolysis
(Takahashi et al., 2016) but is subject to degradation by CMA
(Kaushik and Cuervo, 2016).
LD SIZE INFLUENCES ITS MODE OF
CATABOLISM
In liver cells LD size varies widely from about 60 nanometers
to more than 20,000 nanometers (20 microns) in diameter.
Larger LDs are readily seen in liver histology sections from
ethanol-fed rodents (Donohue et al., 2007a) and in liver
biopsies of people with alcohol use disorders (AUDs) (Torruellas
et al., 2014). Evidence now indicates that LD size influences
which lipolytic pathway initiates LD breakdown. A recent
investigation by Schott et al. (2017) (AASLD abstract; MS
under review) revealed that autophagosomes and multivesicular
bodies (MVB)/late endosomes, selectively sequester smaller-
sized LDs, while larger LDs more frequently interact with
the cytosolic adipocyte triglyceride lipase, (ATGL) the rate-
limiting enzyme in triglyceride lipolysis. Thus, ATGL appears
to preferentially lipolyze the contents of larger LDs, reducing
them to sizes that allow their terminal sequestration into
autophagosomes. These findings imply that the breakdown of
very large LDs, such as those seen in livers with alcohol-induced
macrovesicular steatosis proceeds by a sequential lipolysis-to-
lipophagy mechanism.
The physio-biochemical causes of alcohol-induced LD
enlargement can be traced partially to disruption of LD
breakdown. Listenberger et al. (2018) reported that ethanol-
induced LD enlargement is, in part, the result of decreased
lipolysis, which coincides with a significant reduction in
the phosphatidylcholine (PC) to phosphatidylethanolamine
(PE) ratio in LD membranes of ethanol-fed animals. LDs
that lack sufficient PC to shield internal lipid stores exhibit a
tendency to fuse with each other, thereby creating enlarged
LDs that can occupy the entire hepatocyte, pushing the nucleus
to the periphery (Guo et al., 2008; Krahmer et al., 2011;
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FIGURE 3 | Schematic of lipophagy pathways. Shown are the three major
lipophagic pathways: macrolipophagy (right), microlipophagy (left) and
chaperone-mediated autophagy of lipid droplet proteins (top center). Details
of each pathway are described in the text. Direct lipolysis by cytosolic lipases
of a lipid droplet is shown in the center. Figure reproduced from Figure 1 by
Schulze et al. (2017b) with permission. Note: The figure shows steps in the
pathways that are inhibited by ethanol consumption. These are denoted by
the numbered symbols indicated by (EtOH.) In (1) ethanol consumption
blocks CMA by inhibiting AMPK; in (2) ethanol consumption prevents
lysosome biogenesis by inhibiting TFEB; in (3) ethanol consumption impairs
lipolysis by inhibiting ATGL and HSL; in (4) ethanol consumption blocks
mitochondrial fatty acid oxidation by causing mitochondrial damage and
inactivating PPAR- alpha. Details of each are described in the text.
You and Arteel, 2019). Furthermore, the reduction in LD surface
PC:PE ratio on these enlarged LDs is associated with higher
contents of PLIN2 and PLIN3 on the LD membrane. LD-
associated PLINs confer structural integrity to the LD because
they potently inhibit lipase activity (Brasaemle et al., 2009; Hall
et al., 2010). The latter findings have been substantiated in vitro
by studies conducted with liposomes, which model LDs, and
were synthesized with PC:PE ratios identical to those detected
in hepatic LDs of ethanol-fed rats. These analyses revealed that
ethanol-induced changes in the LD phospholipid composition,
contribute directly to quantitative changes in proteins that
associate with the LD surface. Therefore, reducing the ratio
of PC to PE increases PLIN2 and PLIN3 binding to the LD
membrane (Listenberger et al., 2018). Comparable results were
obtained when NIH 3T3 and AML12 cells were exposed to
choline-deficient media, which also decreases the PC:PE ratio
of LDs (Listenberger et al., 2018). Their data showed increased
association of PLINs, and other specific proteins, with LDs.
Taken together, these studies indicate that ethanol-induced
phospholipid alterations on the LD surface (PC:PE ratio) directly
impacts LD size and number by altering the LD surface proteome
and inhibiting lipolytic pathways, including lipophagy.
AUTOPHAGY IS REGULATED BY
ETHANOL OXIDATION
Active autophagy is essential for cell survival because it yields
energy while it recycles substrates required for macromolecular
synthesis. Whether ethanol exposure stimulates or slows
autophagy in vivo or in vitro depends on the duration of ethanol
consumption/exposure, the amount of ethanol administered, and
the manner in which it is administered to animals or cells
(Thomes et al., 2013a, 2015) Acute ethanol consumption, also
called binge drinking, occurs when a large amount of alcohol
is imbibed in a single bolus or at multiple times during a short
(usually two to 12 h) time period (Zakhari and Li, 2007). Acute
ethanol administration to naïve animals, usually performed by
gastric intubation (gavage), accelerates hepatic autophagy (Ding
et al., 2010; Thomes et al., 2015). In contrast, feeding the ethanol
liquid diet (Lieber and DeCarli, 1986) to rodents for several
weeks, retards hepatic autophagy, as judged grossly by liver
enlargement (hepatomegaly), which reflects lipid and protein
accumulation (Baraona et al., 1975; Donohue et al., 1989) and
biochemically by the hepatic accumulation of two autophagy
marker proteins: one is p62/SQSTM (sequestosome), an adaptor
protein and lysosome substrate. The other is the lipidated form
II of microtubule-associated protein 1 light chain 3 (LC3II), a
classical marker of autophagosome content (Rubinsztein et al.,
2009; Thomes et al., 2015; Rasineni et al., 2017).
Autophagy in Cultured Cells
We measured autophagy in ethanol-exposed recombinant VL-
17AADH+/CYP2E1+ cells that metabolize ethanol (Donohue
et al., 2006). Our studies revealed that 24 h or longer
exposure of cells to 50 mM ethanol inhibits autophagy. This
is due, in part, to the ethanol-induced depletion of lysosomes,
which decrease by 50% while autophagosome numbers (seen
microscopically as GFP-LC3II-positive puncta) nearly double
in the same time period (Thomes et al., 2013a) The ethanol-
induced rise in autophagosomes does not occur in parental
Hep G2 cells, which express neither ADH nor CYP2E1.
Similarly, autophagy proceeds normally when ethanol-treated
VL-17A cells are co-treated with 4-methylpyrazole (4-MP)
which blocks ethanol oxidation. LC3II levels also remain
unchanged when reactive metabolites generated by ethanol
oxidation are scavenged, by co-treating VL-17A cells with
glutathione ethyl ester (Thomes et al., 2013a). The latter findings
clearly indicate that blocking acetaldehyde/ROS formation
or enhancing the removal of these metabolites avoids the
disruptive effects of ethanol oxidation on autophagy in ethanol-
metabolizing VL-17A cells.
Autophagy in vivo
More recent studies by Guo et al. (2015) showed that autophagy
either slows down or proceeds normally in response to the level
of acetaldehyde flux generated during ethanol metabolism. They
report that ethanol-fed mice carrying the ALDH2 transgene
exhibit significantly lower levels of blood and liver acetaldehyde
than identically-treated controlmice, carrying the friendly virus B
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(FVB) viral vector, without the ALDH2 transgene. These findings
suggest that ALDH2 transgenic mice clear acetaldehyde more
rapidly than FVB control mice. Livers from ethanol-fed ALDH2
transgenic mice exhibit normal (control) levels of autophagy
markers and a threefold reduction in hepatic triglycerides,
compared with ethanol-fed FVB mice.
In vitro studies by these investigators revealed that direct
ethanol (100 mM) or acetaldehyde (100 or 500 µM) exposure
to ethanol-metabolizing VA-13ADH+/CYP2E1− cells, suppressed
intracellular autophagy, while exposure to each compound
caused increased cellular expression of interleukin-6 (IL-6),
a pro-inflammatory marker (Osna et al., 2017). Both the
latter responses were alleviated when ethanol or acetaldehyde-
treated VA-13 cells were co-treated with the autophagy
activator rapamycin or with the ALDH2 activator Alda-1.
Their findings suggest that autophagy/lipophagy is suppressed
by metabolically-derived acetaldehyde. However, accelerated
acetaldehyde clearance by higher intrahepatic levels of ALDH2
or by Alda-1-activated ALDH2, prevents ethanol/acetaldehyde-
elicited autophagy retardation and liver cell injury. The
striking reduction in liver triglycerides in ethanol-fed ALDH2
transgenic animals, suggests that the reduction in the amount
of metabolically-generated acetaldehyde allows lipophagy and
subsequent lipolysis to proceed normally.
Other Metabolic Considerations
The study just described prompts the question of whether
enhanced acetate formation due to accelerated acetaldehyde
oxidation contributes to autophagy activation. This appears
unlikely, as we reported that direct exposure of VL-17A cells to
10 mM acetate causes no change in LC3II content. In contrast,
when we expose VL-17A cells to 100 µM acetaldehyde, LC3II
content rises, indicating autophagy retardation (Thomes et al.,
2013a). Acetate is metabolically converted to acetyl CoA, a
substrate for acetyltransferases, which catalyze the attachment
of acetyl groups to lysine side chains on proteins (Drazic
et al., 2016). There are reports that acetylation of transcription
factor EB influences its activity as the principal regulator of
autophagy and lysosome biogenesis (discussed later in this
review). However, published findings report mixed results.
Some declare that acetylation of TFEB reduces its activity
(Bao et al., 2016), while others assert that this modification
activates the transcription factor (Li et al., 2017a,b). For
now, our data indicate that excess acetate, by itself, does
not influence autophagy, but studies designed to critically
examine the incorporation of acetate derived directly from
ethanol oxidation into acetyl CoA and subsequently into
acetylated proteins, will likely reveal a more definitive answer
to this question.
CHRONIC ETHANOL
CONSUMPTION/EXPOSURE DISRUPTS
LIPOPHAGY
There is solid evidence that, similar to affecting bulk autophagy,
chronic ethanol consumption retards the lipophagic clearance of
LDs. An in vitro study by McVicker et al. (2012) used alcohol-
metabolizingWIFB cells to demonstrate that ethanol oxidation is
strongly associated with impaired fat clearance and accumulation
of LDs and of the lipid droplet protein PLIN2 (a.k.a. adipocyte
differentiation related protein; ADRP in this paper). Their
findings led them to suggest that ethanol metabolism retards
lipophagy. Related to this report are several others that similarly,
indicate that ethanol consumption by rodents not only disrupts
the structural integrity of liver lysosomes (Donohue et al., 1994,
2007a; Kharbanda et al., 1995, 1997), but also retards lysosome
biogenesis in vivo (Kharbanda et al., 1996; Chao et al., 2018b) and
in cultured cells (Thomes et al., 2013a).
Ex vivo Studies Show Lipophagy
Impairment by Chronic Ethanol
Administration
Rasineni et al. (2017) reported that the clearance of LDs
(as judged by triglyceride disappearance), in hepatocytes from
ethanol-fed rats was slower than that in cells from pair-
fed control animals. The latter finding was associated with
lower intracellular levels of the active (phosphorylated) form
of dynamin-2 (Dyn-2), a GTPase that catalyzes the scission of
autolysosomes to sustain autophagic lysosome regeneration, a
process that essentially “recycles” lysosomes from pre-existing
autolysosomes (Chen and Yu, 2017). They also reported that
hepatocytes from ethanol-fed rats contained lower levels than
controls of the phosphorylated form of Src kinase, which
phosphorylates, and activates Dyn-2. Consequently, hepatocytes
of ethanol-fed rats contained 42% fewer lysosomes and 40–66%
higher levels of the autophagy marker/substrate proteins LC3II
and p62 than cells from pair-fed control animals. Their data
indicate an ethanol-elicited retardation of LD degradation that
likely results, in part, from faulty lysosome regeneration, adding
to the previously-reported ethanol-induced decline in de novo
lysosome biogenesis in livers of ethanol-fed rats (Kharbanda
et al., 1996). Similar findings were recently reported in mice
(Chao et al., 2018a,b), using the chronic ethanol feeding,
followed by ethanol binge (NIAAA) feeding model of ethanol
administration (Bertola et al., 2013a,b; Gao et al., 2017). The
latter feeding regimen to rodents reportedly recapitulates the
drinking patterns, as well as the degree of liver injury in
humans with AUDs.
Related work by Schulze et al. (2017a) found that chronic
ethanol consumption impairs Rab7, a small GTPase that
facilitates lysosome recruitment to the LD. They report
that hepatocytes from ethanol-fed rats exhibit lysosome
clustering, suggesting a partial blockage of lysosome mobility
and dispersion. They also detected a 50% decline in Rab7 activity
in fasted (lipophagy-activated) hepatocytes from ethanol-fed
rats, compared with identically-treated hepatocytes from
control rats. Together, their findings indicate that ethanol
exposure negatively affects GTPases that have accessory roles
in lysosome function. These findings further support the
notion that ethanol consumption significantly disrupts the
degradative (lysosomal) phase of lipophagy. Their reported
findings of ethanol-induced disruption in lysosome mobility
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also indicate an ethanol-elicited decline in trafficking of these
organelles by microtubules. As mentioned earlier, acetaldehyde,
the primary oxidation product of ethanol oxidation, blocks
polymerization of microtubule subunits into active molecular
motors by forming adducts with the alpha tubulin subunit
(Smith et al., 1989; Figure 2).
Chronic Ethanol Consumption Retards
Triglyceride Breakdown (Lipolysis) and
Fatty Acid Oxidation
Lipophagic degradation of LDs, yields free triglycerides and
cholesteryl esters. These are hydrolyzed by lipases and esterases,
respectively, generating free cholesterol, and high-energy fatty
acids. Each fatty acid is activated by conjugation to coenzyme
A (CoA), forming a fatty-acyl CoA, which is transported into
the mitochondrion. There, it undergoes a stepwise series of beta
(β) oxidations and cleavages, producing multiple two-carbon
units of acetyl-CoA, which enter the Krebs cycle to generate
ATP. Thus, the oxidative breakdown of one mole of palmitate,
a C16 fatty acid, yields eight moles of acetyl CoA, to generate
96 moles of ATP. This is four-times more ATP than that yielded
by the oxidation of one mole of glucose, a C6 monosaccharide
(Devlin, 1992).
Ethanol consumption impedes triglyceride (TG) breakdown,
as demonstrated by Schott, et al. who reported that β-adrenergic
activation of the cytosolic ATGL and phosphorylation of the
hormone-sensitive lipase (HSL) are lower in hepatocytes from
ethanol-fed rats than in cells from pair-fed controls (Schott et al.,
2017). These findings are closely linked to a reduction in LD
breakdown in these cells.
Furthermore, chronic ethanol consumption impairs the
mitochondrial oxidation of fatty acids released from hydrolyzed
TGs by causingmitochondrial depolarization (Zhong et al., 2014)
and by dysregulating the function of the peroxisome proliferator
activated receptor alpha/retinoid X receptor (PPAR-α/RX
receptor) a transcriptional regulator that governs expression
of enzymes that catalyze FAO (Fischer et al., 2003). Evidence
suggests that such disruption by alcohol administration is caused,
in part, by direct binding ofmetabolically-generated acetaldehyde
to PPAR-α, thereby diminishing its ability to bind target DNA
sequences used to transcribe mRNAs that encode FAO enzymes
(Galli et al., 2001).
Chronic Ethanol Administration Lowers
the Nuclear Content of Transcription
Factor EB (TFEB)
Transcriptional regulators of autophagy/lipophagy belong to
the microphthalmia-associated/TFE subfamily of basic/helix-
loop-helix/leucine zipper transcription factors. These include
transcription factors EB and E3 (TFEB and TFE3) in mammals.
TFEB is the major transcription factor which activates genes that
encode proteins involved in autophagy, lysosome biogenesis and
mitochondrial biogenesis (Settembre et al., 2011, 2012; Settembre
andMedina, 2015). It was also demonstrated that TFEB promotes
lipophagy (Settembre et al., 2013).
Our laboratory examined the levels of intranuclear
(transcriptionally active) and cytosolic (inactive) TFEB in
livers of C57Bl/6 mice subjected to acute and chronic ethanol
administration. Interestingly, our analyses revealed that,
compared with vehicle-gavaged control mice, TFEB nuclear
content was elevated in livers of acutely-treated, ethanol-
gavaged mice. These findings are consistent with similar studies
conducted previously (Ding et al., 2010) and indicate that sudden
hepatic oxidant stress in naïve animals enhances autophagy in
liver, which was confirmed by changes in autophagy markers,
LC3II and P62. Additionally, it is noteworthy that proteasome
activity was unaffected in livers of acutely ethanol-gavaged
mice. We obtained contrasting results, after subjecting mice
to chronic ethanol feeding for 5–9 week. Liver nuclei of
ethanol-fed mice exhibited lower nuclear TFEB content than
pair-fed control mice Proteasome activity in livers of ethanol-fed
animals was also significantly lower than pair-fed control mice
(Thomes et al., 2015).
Recently, we examined the recovery from alcohol-induced
steatosis in 6 week ethanol-fed Wistar rats, some of which
were withdrawn from ethanol and fed control diet for 7 days.
Figures 4A,B show that nuclear TFEB content in livers of
ethanol-fed rats was three-fold lower than in pair-fed control
rats, while the level of cytosolic TFEB in ethanol-fed rats
was higher (Figure 4C), despite the fact that the level of
mRNA that encodes TFEB was twofold lower in ethanol-fed
rats than controls (data not shown); see Thomes et al. (2019).
Figures 4A,B also demonstrate that nuclear TFEB levels returned
to normal after 7 days of refeeding the control diet. Furthermore,
Figure 4D illustrates a similar pattern of decline and restoration
of proteasome activity in ethanol-fed rats, respectively, before and
after 7 days of refeeding the control diet.
The question that arises from these studies is what
mechanism(s) is/are responsible for the decline in nuclear TFEB
content in chronically ethanol-fed rats and mice? Figure 5
provides a likely scenario: The entry of TFEB into the nuclear
compartment is blocked by its phosphorylation, catalyzed
principally by the mechanistic target of rapamycin (mTOR),
the “master kinase” that suppresses autophagy (Kim and Guan,
2015). Unphosphorylated TFEB in the cytosol can freely enter
the nucleus to enhance coordinated lysosomal expression and
regulation (CLEAR) gene transcription (Settembre and Medina,
2015), while its inactive, phosphorylated form remains in the
cytosol, along with unphosphorylated TFEB produced by de
novo synthesis.
Sha et al. (2017) demonstrated that the steady-state
intracellular content of TFEB is principally regulated in
the cytosol by the UPS. They report that a chaperone-
dependent E3 ubiquitin ligase, STIP1 homology and U-Box
containing protein 1 (STUB1) modulates TFEB content by
preferentially ubiquitylating its phosphorylated form as a
signal for degradation by the 26S proteasome. Thus, if either
STUB1 or the 26S proteasome is inactivated, undegraded,
phosphorylated TFEB accumulates in the cytosol thereby
preventing autophagy gene activation by blocking the nuclear
entry of unphosphoryated (active) TFEB. The latter scenario
is possible because excess inactive TFEB monomers form
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FIGURE 4 | Effect of chronic ethanol administration on the nuclear and cytosolic levels of TFEB in rats subjected chronic ethanol feeding and withdrawal.
(A) Western blots of nuclear and cytosolic TFEB in livers of rats fed control diet ethanol diet and rats fed ethanol diet and then withdrawn from ethanol and fed
control diet for 7 days. (B)–mean levels of nuclear TFEB, (C) mean levels of cytosolic TFEB, and (D) mean hepatic proteasome activities in the three groups of
animals, as indicated (figure reproduced from Figure 4 by Thomes et al., 2019 with permission).
FIGURE 5 | Proposed model for the impairment of TFEB nuclear content by ethanol oxidation. (A) In the absence of ethanol, phosphorylated (inactive) TFEB
(p-TFEB; yellow circles) is selectively ubiquitylated and degraded by the ubiquitin-proteasome system (UPS) in the cytosol, allowing translocation of active TFEB
(green circles) into the nucleus to enhance transcription of CLEAR genes. (B) Chronic ethanol oxidation inhibits proteasome activity, which causes p-TFEP
accumulation in the cytosol, resulting in heterodimer formation between pTFEB and active TFEB, thus preventing nuclear translocation of active TFEB and
transcription of CLEAR genes (figure adapted from Figure 9 by Sha et al., 2017 with permission).
heterodimers with unphosphorylated TFEB monomers
(Sha et al., 2017), thereby blocking the nuclear entry of
active TFEB to initiate autophagy. Because chronic ethanol
consumption/oxidation generates oxidants that inhibit liver
proteasome activity (Figures 4C, 5; Donohue et al., 1998, 2007b;
Osna et al., 2004; Donohue, 2005; Thomes et al., 2015) such
inhibition likely influences the ethanol-induced depletion of
nuclear TFEB and the accumulation of cytosolic TFEB. This
same scenario also partially explains why nuclear TFEB is either
unaffected (or even rises) after acute ethanol treatment, as
hepatic proteasome activity is unchanged by ethanol gavage
(Thomes et al., 2012). Additionally other factors prevail under
acute and chronic conditions, as we described before (Thomes
et al., 2015) to explain these contrasting results.
ACTIONS AND AGENTS THAT
ALLEVIATE ETHANOL-INDUCED
AND/OR DIET-INDUCED STEATOSIS
Actions
Withdrawal of ethanol from ethanol-fed rats (Thomes et al.,
2019) and humans rather rapidly and almost completely resolves
their steatosis (Kirchgesner and Danse, 2014; Thiele et al.,
2018) to suggest that the absence of ethanol oxidation allows
resumption of normal lipophagy after ethanol withdrawal.
Agents
The following are dietary and other natural or synthetic agents
that are reported to enhance autophagy. None have been
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rigorously tested in humans with AUD, but some have undergone
testing in ethanol-fed animals.
Dietary Components
Caffeine is a well-known component of coffee (Gonzalez de
Mejia and Ramirez-Mares, 2014). Caffeine is believed to block
mTOR signaling thereby stimulating lipophagy and FAO in mice
(Sinha et al., 2014). Two meta-analyses in humans with NAFLD
revealed that caffeine consumption alone does not affect liver
fibrosis that arises from NAFLD. Interestingly, others report that
regular coffee consumption provides protection against NAFLD-
associated fibrosis (Marventano et al., 2016; Shen et al., 2016).
Most of the latter findings indicate that, in addition to caffeine,
other non-caffeine components in coffee are hepatoprotective
(Chen et al., 2014).
Zinc is an essential metal that has a hepatoprotective
effect when it is supplemented in the diets of human AUD
patients and ethanol-fed rodents (McClain et al., 2017).
Dietary supplematation with zinc reportedly reactivates PPAR-
α, to stimulate β-oxidation of fatty acids, thereby attenuating
ethanol-induced steatosis (Kang et al., 2009). Zinc, is also
critical for lysosome acidification and biogenesis in mammary
tissue (Rivera et al., 2018) to suggest that, by itself, zinc
stimulates autophagy/lipophagy. The latter effect of zinc must be
confirmed in liver.
Plant-Derived Agents
Corosolic acid is a compound extracted from the leaves of the
banaba tree (Langertroemia speciosa L). The chemical protects
the liver from alcoholic-induced liver injury, in part by subduing
apoptosis and restoring hepatic autophagy after activating the
AMP-activated protein kinase (AMP kinase). The latter enzyme
suppresses mTORC1 activity, which allows autophagy activation
(Guo et al., 2016).
Li et al. (2019) tested the efficacy of quercitin, a flavonoid
found in fruits, vegetables, red wine, and herbal medications, on
autophagy in livers of 15 week ethanol-fed C57Bl/6 mice. They
report that quercitin, administered by gavage, effectively reversed
the ethanol-induced blockade of TFEB nuclear localization,
restoring both lysosome function and autophagic flux to normal.
Salvianolic acid A is a is a water-soluble phenolic carboxylic
acid extracted from Salvia miltiorrhiza. It has been tested in
ethanol-fed rats and is reported to ablate alcohol-induced liver
injury by reducing alcohol-induced steatosis by enhancing
autophagosome-lysosome fusion after restoring lysosomal
cathepsin activities (Shi et al., 2018).
Repurposed Compounds
Lin et al. tested the effects of the autophagy inducers
carbamazepine (an anti-seizure medication) and rapamycin (an
immunosuppressant that blocks mTORC1). They also tested the
lysosome inhibitor chloroquine, the antimalarial drug, which
causes a rise in intralysosomal pH, on alcohol and diet-induced
steatosis and injury (NAFLD). Their analyses revealed that
treatment with the autophagy inducers attenuated fatty liver
and injury in both models of AFLD and NAFLD. In contrast,
chloroquine treatment exacerbated steatosis in these animals, but
its effects were reversed by co-treatment with carbamezapine
(Lin et al., 2013).
Nanoformulated Compounds
A comprehensive study by Wang et al. (2018) used a
nanotechnology-enabled high throughput screen to test
15,000 compounds to identify those that activate TFEB. Three of
these, digoxin, a cardiac glycoside used to treat atrial fibrillation,
ikarugamycin, a natural antibacterial/anti-protozoan agent,
used to treat infections, and alexidine dihydrochloride, an
inhibitor of protein tyrosine phosphatase localized to the
mitochondrion, activated TFEB, each by a distinct calcium-
dependent mechanism. When the latter compounds were
each formulated into nanoparticles and used to treat animals,
each of them conferred hepatoprotection from diet-induced
steatosis in mice and extended the lifespan of the roundworm
Caenorhabditis elegans (C elegans). Whether these latter
compounds would be effective agents to treat alcohol-induced
fatty liver remains to be tested.
SUMMARY AND FUTURE DIRECTIONS
It is evident that autophagy is critical for maintaining normal
liver function and it has a crucial role in ablating fatty liver
disease that arises from excessive drinking. Although autophagy
activity in the alcohol-induced fatty liver is affected by the
duration of ethanol consumption/exposure, the amount of
ethanol administered, and the way in which it is administered,
there is solid evidence that chronic ethanol consumption retards
the lipophagic/autophagic clearance of LDs that accumulate
during the pathogenesis of alcohol-induced fatty liver. The
reasons for retarded removal of LDs are threefold: (1) Ethanol
oxidation disrupts the autophagic/lipophagic machinery (e.g.,
lysosomes) that degrade LDs; (2) alcohol-metabolism changes
the phospholipid composition of the LD membrane, which,
in turn, alters its content of resident proteins, conferring
greater membrane resistance to lipophagy and lipolysis; and (3)
ethanol metabolism thwarts the mitochondrial oxidation of fatty
acids extracted from LDs by inhibiting PPAR-α and disrupting
mitochondrial function.
While it is clearly evident that chronic alcohol consumption
disrupts lipophagy, which contributes to alcohol-induced
steatosis, the specific ethanol metabolite(s) that cause(s) such
disruption(s) have/has yet be unequivocally identified. Strong
circumstantial evidence, cited here, implicates metabolically-
derived acetaldehyde as the offending agent. The challenges to
confirming acetaldehyde as the sole autophagy disruptor are: (1)
its volatility (bp = 21◦C); (2) the high sensitivity required for its
detection in vivo in its free and adducted forms. (3) detecting
acetaldehyde or MAA adducts on specific autophagy/lipophagy-
related proteins; and (4) defining whether such modifications
influence the biological functions of these proteins.
Both acute and chronic alcohol consumption increase
ROS production, which leads to oxidant stress. Our previous
findings indicate that blocking acetaldehyde/ROS formation or
enhancing their removal, avoids the disruptive effects of ethanol
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oxidation on autophagy in ethanol-metabolizing cells. Studies
have clearly shown that ethanol oxidation significantly disrupts
the degradative (lysosomal) phase of autophagy/lipophagy.
Abstinence from alcohol along with proper pharmacological
(Johnson, 2010) and behavioral therapies (Hagedorn et al., 2016)
can effectively minimize recidivism and reverse steatosis in
people with AUDs. Our animal studies, revealed that ethanol
withdrawal from ethanol-fed rats almost completely resolves
their steatosis after 7 days (Thomes et al., 2019). These
findings also suggest that cessation of ethanol consumption
restores lipophagy rates to normal, thereby accelerating the
removal of excess LDs.
Finally, evidence, mostly from animal studies, but some
human studies, suggest that caffeine/coffee, resveratrol, corosolic
acid, zinc, carbamazepine, and rapamycin, individually activate
autophagy/lipophagy and may also be used to prevent and
treat alcohol-induced fatty liver. The clinical utility of these
aforementioned compounds and of those tested recently
(Wang et al., 2018) appear to have therapeutic promise but
those that were most recently discovered to activate TFEB
(Wang et al., 2018) must be tested for safety and efficacy
in human trials.
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